Yang, Jingjing
Lin, Lili
Long, Qihe
Zhang, Qian
Sun, Guilan
Zhou, Liang
Wang, Qingyu
Zhu, Jun
Li, Fanfan
Clinical trials referenced in this document:
Documents that mention this clinical trial
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
https://doi.org/10.1007/s40259-022-00534-w
Article History
Accepted: 13 April 2022
First Online: 20 May 2022
Declarations
:
: This study was funded by Shanghai Henlius Biotech, Inc.
: Guilan Sun, Liang Zhou, Qingyu Wang, and Jun Zhu are employees of Shanghai Henlius Biotech, Inc. All other authors declare that there are no conflicts of interest.
: This study was approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (Hefei, China) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: All participants provided informed consent before undergoing any study-specific procedures.
: Data are available from the corresponding author on reasonable request.
: Not applicable.
: The manuscript was developed under the primary guidance of WH and FL. Material preparation, data collection, and analysis were performed by JY, LL, QL, QZ, GS, LZ, QW, and JZ. All authors reviewed and provided comments on the manuscript. All authors read and approved the final manuscript.